Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/II Trial of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer

NCT01326871 is registered in ClinicalTrials.gov with Altor BioScience as lead sponsor.

NCT NCT01326871
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01326871 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/II Trial of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer
Lead sponsor
Altor BioScience
Phase
Phase 1/2
Overall status
Completed
Start date
September 6, 2011
Completion date
April 11, 2016
Enrollment
68 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

malignant tumor of renal pelvis, transitional cell carcinoma of bladder, ureter cancer, urethra cancer